吸入信必可都保对中重度稳定期慢性阻塞性肺疾病的肺功能临床分析

目的观察信必可都保（布地奈德／福莫特罗）对中重度稳定期慢性阻塞性肺疾病（COPD）患者肺功能的改善作用。方法将94例中重度稳定期COPD患者随机分为观察组和对照组，每组各47例，两组均进行吸氧、止咳、平喘、祛痰等常规治疗，观察组在此基础上加用信必可都保（布地奈德160μg／福莫特罗4．5μg），1吸／次，2次／d，治疗周期为12周，治疗结束后比较两组PaO2、PaCO2等血气指标及FVC、FEV1、FEV1／FVC％肺功能改善情况。结果治疗后，两组血气指标及肺功能均较治疗前有不同程度的改善，观察组PaO2（84．56±8．55）mmHg、PaCO2（30．25±3．26）mmHg及FVC（2．91±0．35）L、FEV1（2．02±0．24）L、FEV1／FVC％（72．14±7．41）％等与对照组比较，差异有统计学意义（P〈0．05）。结论信必可都保可有效缓解中重度稳定期COPD病情，有效改善其肺功能及血气各项指标。

Clinical Analysis of Lung Function in The Treatment by Inhaling The Symbicort Turbuhale in Patients with Moderate to Severe Stable Chronic Obstructive Pulmonary Disease

Objective To observe the impaction of Symbicort Turbuhale（Budesonide/Formoterol）on the lung function of moderate to severe stable chronic obstructive pulmonary disease（COPD）. Methods 94 patients with moderate to severe stable COPD were randomly divided into observation group and control group, 47 cases in each group. Two groups were treated with oxygen, cough, asthma, expectorant and other conventional treatment. The observation group were treated with Symbio,Turhuhaler（Budesonide 160 μg/Formoterol 4.5 μg）in the basis of the conventional treatment. The changes of the blood gas indicators such as PaO2, PaCO2 and the lung function index such as FVC, FEV1, FEV1/FVC% were compared after the treatment. Results After treatment, the blood gas indicators and the lung function index of patients in the two groups improved,and the blood gas indicators such as PaO2 （84. 56±8.55 mmHg） ,PaCO2 （30.25±3. 26 mmHg）and the lung function index such as FVC（2. 91±0. 35 L）, FEVI（2. 02±0. 24 L）, FEV1/FVC1 （ 72. 14 ± 7.41% ） of the observation group improved more significantly than the control group （ P 〈 0. 05 ）. Conclusion Symbicort Turbuhale is effective in improving lung function in patients with moderate to severe stable COPD and the blood gas indicators.